Login to Your Account

Astrazeneca 'Acerta[s]' its ambitions in blood cancer with $4B deal

By Michael Fitzhugh
Staff Writer

Thursday, December 17, 2015

Astrazeneca plc is buying 55 percent of privately held Acerta Pharma LLC, the developer of acalabrutinib, a phase III oral small-molecule BTK inhibitor that it expects to transform the treatment of B-cell malignancies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription